Cost-effectiveness of eculizumab and efgartigimod for the treatment of anti–acetylcholine receptor antibody–positive generalized myasthenia gravis

Eculizumab and efgartigimod were approved to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis (anti-AChR Ab-positive gMG). These relatively new biological treatments provide a more rapid onset of action and improved efficacy compared with conventional immunosuppressive treatments, but at a higher cost.